Founders Capital Management Has $2.28 Million Position in Pfizer Inc. (NYSE:PFE)

Founders Capital Management cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,011 shares of the biopharmaceutical company’s stock after selling 808 shares during the quarter. Pfizer comprises 1.7% of Founders Capital Management’s portfolio, making the stock its 22nd biggest holding. Founders Capital Management’s holdings in Pfizer were worth $2,275,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Pfizer by 0.6% during the 1st quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock valued at $18,171,704,000 after acquiring an additional 2,516,132 shares during the period. Wellington Management Group LLP lifted its position in shares of Pfizer by 9.8% during the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock valued at $8,932,423,000 after acquiring an additional 19,602,359 shares during the period. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Geode Capital Management LLC lifted its position in shares of Pfizer by 0.5% during the 1st quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock valued at $4,472,433,000 after acquiring an additional 577,201 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 14.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock valued at $3,408,836,000 after acquiring an additional 10,560,702 shares during the period. 68.05% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.4 %

Shares of NYSE:PFE opened at $34.03 on Friday. The business’s 50 day simple moving average is $35.83 and its two-hundred day simple moving average is $38.04. The firm has a market cap of $192.13 billion, a P/E ratio of 9.05, a PEG ratio of 1.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. Pfizer Inc. has a 52-week low of $33.54 and a 52-week high of $54.93.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.10. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company’s quarterly revenue was down 54.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.04 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were issued a $0.41 dividend. The ex-dividend date was Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.82%. Pfizer’s dividend payout ratio is presently 43.62%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research report on Tuesday, September 5th. Truist Financial restated a “buy” rating and set a $62.00 price objective on shares of Pfizer in a research report on Wednesday. BMO Capital Markets dropped their price objective on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a research report on Wednesday, August 2nd. Jefferies Financial Group dropped their price objective on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Finally, HSBC began coverage on Pfizer in a research report on Friday, July 14th. They set a “buy” rating and a $50.00 price objective for the company. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $46.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.